RxDoctor Payments Data

Rakhshi Hydari, MD

Family Medicine · Sherman, TXNPI 1699945956

Payments from drug & device makers

$2,175in general payments, 2019–2025

Across 81 payments — averaging $26.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$664
  • AstraZeneca$167
  • Mylan Specialty L.p.$153
  • Boehringer Ingelheim$145
  • GSK$136
  • Novo Nordisk$127
  • plus $783 from 20 others
$1,358in research payments, 2019–2025

Across 1 payment — averaging $1358.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1K

What the payments were for

  • Food & beverage$1,511100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,175 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$230,720
Medicare patients
157
Services billed
2,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban238$69,889
RybelsusSemaglutide51$51,613
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$49,878
Abilify MaintenaAripiprazole15$41,592
OzempicSemaglutide40$41,295
RexultiBrexpiprazole32$37,345
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$33,868
FarxigaDapagliflozin Propanediol57$24,799
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$19,986
LinzessLinaclotide27$15,035
Divalproex Sodium200$12,732
JanuviaSitagliptin Phosphate12$9,448
TradjentaLinagliptin35$9,041
Potassium Chloride353$7,919
Pantoprazole Sodium354$7,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$127$92,90891 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$70$78,93747 claims
PfizerEliquis$49$69,889238 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$167$48,14797 claims
GSKTrelegy Ellipta$136$33,86852 claims
Boehringer IngelheimTradjenta, Jardiance$145$16,60160 claims
AbbVieLinzess$26$15,03527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sherman

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →